Overview

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
2016-06-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Clovis Oncology, Inc.
Collaborator:
Novartis Pharmaceuticals
Treatments:
Trametinib